Search Results - Russell Z. Szmulewitz

Refine Results
  1. 1
    Targeting the glucocorticoid receptor in breast and prostate cancers

    Targeting the glucocorticoid receptor in breast and prostate cancers by Jacob Kach, Suzanne D. Conzen, Russell Z. Szmulewitz

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    A Randomized Phase 1 Study of Testosterone Replacement for Patients with Low-Risk Castration-Resistant Prostate Cancer

    A Randomized Phase 1 Study of Testosterone Replacement for Patients with Low-Risk Castration-Resistant Prostate Cancer by Russell Z. Szmulewitz, Supriya G. Mohile, Edwin M. Posadas, Rangesh Kunnavakkam, Theodore Karrison, Elizabeth Manchen, Walter M. Stadler

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    National trends in prostate cancer screening among older American men with limited 9‐year life expectancies: Evidence of an increased need for shared decision making

    National trends in prostate cancer screening among older American men with limited 9‐year life expectancies: Evidence of an increased need for shared decision making by Michael W. Drazer, Sandip M. Prasad, Dezheng Huo, Mara A. Schonberg, William Dale, Russell Z. Szmulewitz, Scott E. Eggener

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate Cancer

    Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate Cancer by Masis Isikbay, Kristen Otto, Steven Kregel, Jacob Kach, Yi Cai, Donald J. Vander Griend, Suzanne D. Conzen, Russell Z. Szmulewitz

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Serum/glucocorticoid‐regulated kinase 1 expression in primary human prostate cancers

    Serum/glucocorticoid‐regulated kinase 1 expression in primary human prostate cancers by Russell Z. Szmulewitz, Elizabeth Chung, Hikmat Al‐Ahmadie, Silver Daniel, Masha Kocherginsky, Aria Razmaria, Gregory P. Zagaja, Charles B. Brendler, Walter M. Stadler, Suzanne D. Conzen

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Sox2 Is an Androgen Receptor-Repressed Gene That Promotes Castration-Resistant Prostate Cancer

    Sox2 Is an Androgen Receptor-Repressed Gene That Promotes Castration-Resistant Prostate Cancer by Steven Kregel, Kyle J. Kiriluk, Alex M. Rosen, Yi Cai, Edwin E. Reyes, Kristen Otto, Westin R. Tom, Gladell P. Paner, Russell Z. Szmulewitz, Donald J. Vander Griend

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer

    Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer by Steven Kregel, James L. Chen, Westin R. Tom, Venkatesh Krishnan, Jacob Kach, Hannah Brechka, Tim Fessenden, Masis Isikbay, Gladell P. Paner, Russell Z. Szmulewitz, Donald J. Vander Griend

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer

    Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer by Anthony V. Serritella, Daniel H. Shevrin, Elisabeth I. Heath, James L. Wade, Elia Martinez, Amanda Anderson, Joseph D. Schonhoft, Yen-Lin Chu, Theodore Karrison, Walter M. Stadler, Russell Z. Szmulewitz

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer

    PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer by Santosh Gupta, Susan Halabi, Qian Yang, Akash Roy, Alisa Tubbs, Yamini Gore, Daniel J. George, David M. Nanus, Emmanuel S. Antonarakis, Daniel C. Danila, Russell Z. Szmulewitz, Richard Wenstrup, Andrew J. Armstrong

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study

    Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES... by Arnulf Stenzl, Curtis Dunshee, Ugo De Giorgi, B. Yа. Alekseev, Taro Iguchi, Russell Z. Szmulewitz, Thomas W. Flaig, Bertrand Tombal, Robert Morlock, Cristina Ivanescu, Krishnan Ramaswamy, Fred Saad, Andrew J. Armstrong

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

    ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer by Andrew J. Armstrong, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey M. Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, B. Yа. Alekseev, Taro Iguchi, Neal D. Shore, Brad Rosbrook, Jennifer Sugg, Benoît Baron, Lucy Chen, Arnulf Stenzl

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer

    Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer by Daniel C. Danila, Russell Z. Szmulewitz, Ulka N. Vaishampayan, Celestia S. Higano, Ari David Baron, Houston Gilbert, Flávia Brunstein, Marija Milojic-Blair, Bei Wang, Omar Kabbarah, Michael Mamounas, Bernard M. Fine, Daniel Maslyar, Alexander Ungewickell, Howard I. Scher

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)

    LBA25 Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy... by Andrew J. Armstrong, Taro Iguchi, Arun Azad, Russell Z. Szmulewitz, Jeffrey M. Holzbeierlein, Arnauld Villers, Antonio Alcaraz, B. Yа. Alekseev, Neal D. Shore, Daniel P. Petrylak, Brad Rosbrook, Fabian Zohren, Shunsuke Yamada, Gabriel P. Haas, Arnulf Stenzl

    Published 2021
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer

    Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer by Russell Z. Szmulewitz, Cody J. Peer, Abiola Ibraheem, Elia Martinez, Mark Kozloff, Bradley Curtis Carthon, R. Donald Harvey, Paul A. S. Fishkin, Wei Peng Yong, Edmund Chiong, Chadi Nabhan, Theodore Karrison, William D. Figg, Walter M. Stadler, Mark J. Ratain

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease

    MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease by Raj Bhanvadia, Calvin VanOpstall, Hannah Brechka, Nimrod Barashi, Marc Gillard, Erin M. McAuley, Juan Manuel Vasquez, Gladell P. Paner, Wen‐Ching Chan, Jorge Andrade, Angelo M. De Marzo, Misop Han, Russell Z. Szmulewitz, Donald J. Vander Griend

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3

    Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasm... by John D. Powderly, Gregory M. Coté, Keith T. Flaherty, Russell Z. Szmulewitz, Antoni Ribas, Jeffrey S. Weber, Deryk Loo, Jan Baughman, Francine Chen, Paul A. Moore, Ezio Bonvini, James R. Vasselli, Jon M. Wigginton, Roger B. Cohen, Howard A. Burris, Bartosz Chmielowski

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors

    First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors by Sarina A. Piha‐Paul, Jasgit C. Sachdev, Minal Barve, Patricia LoRusso, Russell Z. Szmulewitz, Sapna P. Patel, Primo N. Lara, Xiaotian Chen, Beibei Hu, Kevin J. Freise, Dimple Modi, Anjla Sood, Jessica E. Hutti, Johannes Wolff, Bert H. O’Neil

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

    Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer by Andrew J. Armstrong, Arun Azad, Taro Iguchi, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey M. Holzbeierlein, Arnauld Villers, Antonio Alcaraz, B. Yа. Alekseev, Neal D. Shore, F. Gómez-Veiga, Brad Rosbrook, Fabian Zohren, Shunsuke Yamada, Gabriel P. Haas, Arnulf Stenzl

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth

    Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth by Jacob Kach, Tiha M. Long, Phillip Selman, Eva Tonsing-Carter, Maria A. Bacalao, Ricardo R. Lastra, Larischa de Wet, Shane Comiskey, Marc Gillard, Calvin VanOpstall, Diana C. West, Wen‐Ching Chan, Donald J. Vander Griend, Suzanne D. Conzen, Russell Z. Szmulewitz

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    SOX2 mediates metabolic reprogramming of prostate cancer cells

    SOX2 mediates metabolic reprogramming of prostate cancer cells by Larischa de Wet, Anthony Williams, Marc Gillard, Steven Kregel, Sophia Lamperis, Lisa C. Gutgesell, Jordan E. Vellky, Ryan M. Brown, Kelly O. Conger, Gladell P. Paner, Heng Wang, Elizabeth A. Platz, Angelo M. De Marzo, Ping Mu, Jonathan L. Coloff, Russell Z. Szmulewitz, Donald J. Vander Griend

    Published 2022
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: